The relationship of erythropoietin overexpression with von Hippel-Lindau tumour suppressor gene mutations between hypoxia-inducible factor-1α and -2α in sporadic clear cell renal carcinoma

International Journal of Molecular Medicine

Volumn 26, Issue 6, 2010, Pages 907-912

  Gong, Kan ^a   Zhang, Ning ^b   Zhang, Kai ^c   Na, Yanqun ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Erythropoietin; Hypoxia inducible factor; Kidney carcinoma; Renal cell; Von Hippel Lindau mutation

Indexed keywords

ERYTHROPOIETIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; VON HIPPEL LINDAU PROTEIN;

ARTICLE; CLEAR CELL CARCINOMA; CONTROLLED STUDY; CORRELATIONAL STUDY; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLEX POLYMERASE CHAIN REACTION; MUTATIONAL ANALYSIS; NEPHRECTOMY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; UPREGULATION;

EID: 78649921834     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm_00000541     Document Type: Article

References (20)

1. Latif F, Tory K, Gnarra J, et al: Identification of the von Hippel-Lindau disease tumour suppressor gene. Science 260: 1317-1320, 1993. (Pubitemid 23231974)
2. Linehan WM, Pinto PA, Srinivasan R, et al: Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics. Clin Cancer Res 13: 671-679, 2007.
3. Kim CM, Vocke C, Toress-Cabal C, et al: Expression of hypoxia inducible factor-1alpha and 2alpha in genetically distinct early renal cortical tumours. J Urol 175: 1908-1914, 2006.
4. Carroll VA and Ashcroft M: Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of Hippel-Lindau function: implications for targeting the HIF pathway. Cancer Res 15: 6264-6270, 2006.
5. Lee YS, Vortmeyer AO, Lubensky IA, et al: Coexpression of erythropoietin and erythropoietin receptor in von Hippel-Lindau disease-associated renal cysts and renal cell carcinoma. Clin Cancer Res 11: 1059-1064, 2005.
6. Vogel TW, Vortmeyer AO, Lubensky IA, et al: Coexpression of erythropoietin and its receptor in endolymphatic sac tumours. J Neurosurg 103: 284-288, 2005.
7. Linehan WM, Walther MM and Zbar B: The genetic basis of cancer of the kidney. J Urol 170: 2163-2172, 2003.
8. Gilcrease MZ, Schmidt L, Zbar B , Truong L, Rutledge M and Wheeler TM: Somatic von Hippel-Lindau mutation in clear cell papillary cystadenoma of the epididymis. Human Path 26: 1341-1346, 1995.
9. Prowse AH, Webster AR, Richards FM, et al: Somatic inactivation of the VHL gene in von Hippel-Lindau disease tumours. Am J Hum Genet 60: 765-771, 1997.
10. Hardee ME, Arcasoy MO, Blackwell KL, Kirkpatrick JP and Dewhirst MW: Erythropoietin biology in cancer. Clin Cancer Res 12: 332-339, 2006.
11. Gong K, Zhang N, Zhang Z and Na Y: Co-expression of erythopoietin and erythopoietin receptor in sporadic clear cell renal cell carcinoma. Cancer Biol Ther 5: 582-585, 2006. (Pubitemid 44024710)
12. Lam JS, Pantuck AJ, Belldegrun AS and Figlin RA: Protein expression profiles in renal cell carcinoma: staging, prognosis, and patient selection for clinical profiles. Clin Cancer Res 13: 703-708, 2007.
13. Xi N, Guan W, Ryan CK, Schoen SR, Di'Santagnese PA and Messing EM: Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumour suppressor gene mutations and hypoxia-inducible factor-1α expression in renal cell carcinoma. J Urol 170: 588-592, 2003.
14. Kaelin WG Jr: The von Hippel-Lindau tumour suppressor protein and clear cell renal carcinoma. Clin Cancer Res 13: 680-684, 2007.
15. Hamano K, Esumi M, Igarashi H, et al: Biallelic inactivation of the von Hippel-Lindau tumour suppressor gene in sporadic renal cell carcinoma. J Urol 167: 713-717, 2002.
16. Brauch H, Weirich G, Brieger J, et al: VHL alterations in human clear cell renal cell carcinoma: association with advanced tumour stage and a novel hot spot mutation. Cancer Res 60: 1942-1948, 2000.
17. Rini BI, Jaeger E, Weinberg V, et al: Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status. BJU Int 98: 756-762, 2006.
18. Yao M, Huang Y, Shioi K, et al: Expression of adipose differentiation-related protein: a predictor of cancer-specific survival in clear cell renal carcinoma. Clin Cancer Res 13: 152-160, 2007.
19. Turner KJ, Moore JW, Jones A, et al: Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res 62: 2957-2961, 2002.
20. Ohh M, Park CW, Ivan M, et al: Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2: 423-426, 2002.